In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma In The Brave New World Of Corporatized Care

Executive Summary

Still transforming their organizations to deal with the waning influence of the individual prescriber, pharma commercial leaders now face a new challenge: the growth of the corporate model of care, as large numbers of US physicians exchange the independence of physician-ownership for the predictability of working as employees in larger organizations. Corporate models of care, characterized by more centralized decision making, add a new dimension of customer complexity in an already tough environment.

You may also be interested in...

AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012

The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.

Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY

Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.

Physicians Have Bigger Stake In Patients' Total Care Under Medicare ACOs

One year after the passage of health care reform, recommendations around some of the more far-reaching elements of the legislation are beginning to emerge. One proposal biopharmas cannot afford to ignore: Medicare sanctioned accountable care organizations.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts